Results 211 to 220 of about 1,372,313 (313)

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak   +2 more
wiley   +1 more source

Estimating the economic burden of diabetes in young adults: A global analysis based on the GBD 2021 and a value of statistical life year framework

open access: yesDiabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aims The rising prevalence of diabetes in young adults threatens global health and sustainable development. However, its full macroeconomic impact, especially the welfare losses beyond conventional productivity costs, has not been systematically quantified at a global level. We aimed to estimate the current and future global economic burden of
Hang Guo   +3 more
wiley   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang   +8 more
wiley   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

open access: yesLiver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu   +5 more
wiley   +1 more source

Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial. [PDF]

open access: yesJ Am Heart Assoc
Jamil Y   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy